- Home
- DTSS vs BOLT Comparison
DTSS vs BOLT Comparison
Compare DTSS & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- BOLT
- Stock Information
- Founded
- DTSS 2014
- BOLT 2015
- Country
- DTSS China
- BOLT United States
- Employees
- DTSS N/A
- BOLT N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- BOLT Health Care
- Exchange
- DTSS Nasdaq
- BOLT Nasdaq
- Market Cap
- DTSS 16.5M
- BOLT 16.8M
- IPO Year
- DTSS N/A
- BOLT 2021
- Fundamental
- Price
- DTSS $2.35
- BOLT $0.32
- Analyst Decision
- DTSS
- BOLT Buy
- Analyst Count
- DTSS 0
- BOLT 3
- Target Price
- DTSS N/A
- BOLT $2.50
- AVG Volume (30 Days)
- DTSS 339.5K
- BOLT 812.4K
- Earning Date
- DTSS 05-14-2025
- BOLT 05-12-2025
- Dividend Yield
- DTSS N/A
- BOLT N/A
- EPS Growth
- DTSS N/A
- BOLT N/A
- EPS
- DTSS N/A
- BOLT N/A
- Revenue
- DTSS $56,255,129.00
- BOLT $3,638,000.00
- Revenue This Year
- DTSS N/A
- BOLT N/A
- Revenue Next Year
- DTSS N/A
- BOLT $97.29
- P/E Ratio
- DTSS N/A
- BOLT N/A
- Revenue Growth
- DTSS 144.20
- BOLT N/A
- 52 Week Low
- DTSS $1.63
- BOLT $0.27
- 52 Week High
- DTSS $7.67
- BOLT $0.78
- Technical
- Relative Strength Index (RSI)
- DTSS 54.80
- BOLT 48.17
- Support Level
- DTSS $2.11
- BOLT $0.29
- Resistance Level
- DTSS $2.36
- BOLT $0.33
- Average True Range (ATR)
- DTSS 0.19
- BOLT 0.04
- MACD
- DTSS -0.02
- BOLT 0.00
- Stochastic Oscillator
- DTSS 48.00
- BOLT 31.19
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.